Navigation Links
ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease
Date:12/20/2007

PARIS, December 20 /PRNewswire-FirstCall/ -- ExonHit Therapeutics, a drug and diagnostic discovery company, announced today that it has obtained a regulatory approval to initiate a Phase 2 clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease. EHT 0202 is a compound, with a novel mechanism of action, which has shown benefits on memory and neuronal loss.

This will be the first Phase 2 clinical trial for EHT 0202, it will be a multi-center, double-blind trial, in which 135 patients will be randomized. The trial's primary endpoint is the safety and tolerability of the product when it is administered orally for a 3 month period in conjunction with an acetylcholinesterase inhibitor, the most common therapy used to treat Alzheimer's disease. The trial will also provide preliminary data on EHT 0202's clinical efficacy, in particular regarding its effects on cognition and behaviour.

Alzheimer's disease is a major public heath issue, with a patient population that is expected to grow rapidly in the near future because of the aging population. It is estimated that over 25 million people worldwide, including 860 thousand in France, suffer from Alzheimer's disease or assimilated pathologies. "Medical research has made significant progress in that field, as shown by the number of therapies now available, however their efficacy remains limited. There is thus a significant need for new and innovative therapies, which will not only provide symptomatic relief but also modify the disease's evolution by slowing or even stopping its underlying neurodegenerative process." stated Olivier Sol, MD, Clinical Director ExonHit.

"EHT 0202's pharmacological properties, linked to its GABA-A receptor modulating role, offer a promising approach to restoring the CNS processes that are altered in Alzheimer's disease, such as neuron degeneration and cognition. Indeed, this compound redirects the processing of APP (Amyloid Precursor Prot
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
4. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
5. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
6. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
7. Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
8. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
9. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
10. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
11. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...e/ -- Reportlinker.com announces that a new market..., Neurostimulation - A Global Market Perspectiv...rostimulation---A-Global-Market-Perspective.html ...thused by the growing base of aging population, an...as, Parkinson,s, and Alzheimer,s disease. Widespre...
(Date:12/2/2009)...wire-FirstCall/ -- Peregrine Pharmaceuticals, Inc....ient enrollment in a dose confirmation and dosimet... glioblastoma multiforme (GBM), the deadliest form... antibody linked to a radioisotope being developed...cifically targets cells at the center of brain tum...
(Date:12/2/2009)...ember 2 Gamida Cell announced toda...animal study) safety and,efficacy of a gene therap...nell Medical College and Gamida Cell. The product ... as Cooley,s Anemia. , Gamida Cell is dev...o,populations of stem/progenitor cells. The compa...
(Date:12/2/2009)...re-Asia/ -- The world is going through,extraordina...s part of many,businesses and industries. It turns...immune to the economic downturn, because illness d...t of the difficult times this year, the pharmaceut...amp;D center in Shanghai, the largest of,its kind ...
Breaking Biology Technology:Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
...pril 18 BioDuro & The National Center for,Safety ...ng announce their,receipt of full AAALAC accredita...preclinical toxicology and large animal DMPK for c...resident of Toxicology stated "Although,we have be...it is exciting,to receive this important, internat...
...hers have used the world,s thinnest material to cr...ck and ten atoms wide. , Reporting their peer-rev...Science, Dr Kostya Novoselov and Professor Andre G...e University of Manchester show that graphene can ...idual transistors having a size not much larger th...
... April 17 BrainCells Inc. (BCI), a,biopharmaceuti...dentify and,develop compounds that promote the gro...rvous system (CNS) diseases, announced today that ...n of its Series B financing, bringing,the total to...tes (NEA),along with current investors and Alexand...
Other Biology Technology:BioDuro & The National Center for Safety Evaluation of Drugs Received Full AAALAC Accreditation 2Graphene used to create world's smallest transistor 2BrainCells Inc. Expands Series B Financing to $50 Million 2
(Date:12/2/2009)...sts are reporting the first identification of subs...ion that changes harmless marine bacteria into kil...ears in ACS, Environmental Science & Technology ,...agues note that bleaching already has destroyed up...entists are searching for ways to slow or stop the...
(Date:12/2/2009)...one of your muscles can twitch, before the thought...ny floodgate of sortscalled an ion channelmust ope...et in the chemical signals that spur the cell to a...Standards and Technology (NIST) has allowed scient...mbrane for the first time, potentially offering in...
(Date:12/2/2009)...tist from the University of Salamanca and another ...of predators affects the behaviour of Acanthodact...ev Desert in the Near East. According to the study...nd different prey if they are under pressure from ...ed this result, but until now there had been very ...
Breaking Biology News(10 mins):Nervy research: Researchers take initial look at ion channels in a model system 2Lizards change their diet to avoid predators 2As Lawsuits Hit the MTA Personal Injury Lawyers Consider How Much is Too Much or Too Little 51154 1As Lawsuits Hit the MTA Personal Injury Lawyers Consider How Much is Too Much or Too Little 51154 2As Lawsuits Hit the MTA Personal Injury Lawyers Consider How Much is Too Much or Too Little 51154 3The next health tsunami 3A Noncommunicable diseases 51152 1The next health tsunami 3A Noncommunicable diseases 51152 2Is obesity an oral bacterial disease 3F 51150 1
...n why people are at greater risk of developing can... published today (June 2). , Scientists have disco... protect us from cancer may also determine how lon...y respected journal Science ?open up a new avenue .... , "We have discovered that proteins that preven...
...ect of a paycheck, good grade, or promotion wonder...now identified the brain circuitry responsible for...n the May 4, 2006, Neuron, Alison Adcock and colle... reveal how specific reward-related brain regions ... promote memory formation. , In their studies, th...
... causes of autism remain complex and mysterious, r...cate puzzle. In what they believe to be a signific... disorders" (ASD), researchers have developed a mo...ain hypertrophy characteristic of the disease. , I...da and his colleagues report the results of removi...
Other Biology News:Worm links cancer risk to ageing 2The brain's motivation station 2Mutant mice show key autism traits 2
...A or Isolated Sequence) siRNA Test System is desig...ion of a potential of any DNA sequence to serve as...Current computer-based RNAi target searching algor...selected sequence to be a good target from 30% to ...
...tabilizer is a is a bovine protein-free alternativ...an aqueous solution that contains non-toxic chemic...H 6.6 - 7.2. This product contains a combination ...ioxane as a preservative. StabilGuard Choice Stab...
Mouse Anti-Yersinia pestis F1 antigen Monoclonal Antibody, Unconjugated, Clone YPF19 from Novus Biologicals
...ated for mounting tissue specimens, cell smears, a...stochemical methods for viewing by light microscop...C, that are alcohol-soluble or incompatible with o...lides are cover-slipped forming a coating that fac...
Biology Products: